Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessing the role of external beam radiation therapy in combination with brachytherapy versus brachytherapy alone for unfavorable intermediate-risk prostate cancer.
Andruska N, Michalski JM, Carmona R, Agabalogun T, Brenneman RJ, Gay HA, Fischer-Valuck BW, Baumann BC. Andruska N, et al. Among authors: brenneman rj. Brachytherapy. 2022 May-Jun;21(3):317-324. doi: 10.1016/j.brachy.2021.12.008. Epub 2022 Feb 3. Brachytherapy. 2022. PMID: 35123889 Free PMC article.
Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer.
Fischer-Valuck BW, Baumann BC, Brown SA, Filson CP, Weiss A, Mueller R, Liu Y, Brenneman RJ, Sanda M, Michalski JM, Gay HA, James Rao Y, Pattaras JG, Jani AB, Hershatter B, Patel SA. Fischer-Valuck BW, et al. Among authors: brenneman rj. Eur Urol Open Sci. 2022 Feb 1;37:80-89. doi: 10.1016/j.euros.2021.12.011. eCollection 2022 Mar. Eur Urol Open Sci. 2022. PMID: 35243392 Free PMC article.
Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy.
Andruska N, Agabalogun T, Fischer-Valuck BW, Brenneman RJ, Huang Y, Gay HA, Michalski JM, Carmona R, Baumann BC. Andruska N, et al. Among authors: brenneman rj. Brachytherapy. 2022 Sep-Oct;21(5):617-625. doi: 10.1016/j.brachy.2022.04.001. Epub 2022 May 28. Brachytherapy. 2022. PMID: 35641370 Free PMC article.
Favorable long-term toxicity for salvage low-dose rate prostate brachytherapy for recurrent prostate cancer after external beam radiotherapy from a phase II prospective trial (NRG Oncology/RTOG 0526).
Brenneman RJ, Soffen E, Gay HA, Orio PF 3rd, Christodouleas JP, Baumann JC, Baumann BC. Brenneman RJ, et al. Transl Androl Urol. 2019 Jul;8(Suppl 3):S265-S270. doi: 10.21037/tau.2019.03.14. Transl Androl Urol. 2019. PMID: 31392141 Free PMC article. No abstract available.
Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer.
Fischer-Valuck BW, Rao YJ, Brenneman RJ, Patel PR, Filson CP, Jani AB, Liu Y, Goyal S, Xu K, Weiss A, Kucuk O, Cimmino C, Szabo S, Rossi P, Baumann BC, Pattaras J, Hershatter B, Patel SA. Fischer-Valuck BW, et al. Among authors: brenneman rj. Brachytherapy. 2020 Sep-Oct;19(5):557-566. doi: 10.1016/j.brachy.2020.05.007. Epub 2020 Jul 3. Brachytherapy. 2020. PMID: 32624405
35 results